Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG

Roland B. Walter, MD PhD MS, Megan Othus, PhD, Bob Löwenberg, MD PhD, Gert J Ossenkoppele, MD PhD, Stephen H. Petersdorf, MD, Thomas Pabst, MD, Marie-Christianne Vekemans, MD, Frederick R. Appelbaum, MD, Harry P. Erba, MD PhD, Elihu H. Estey, MD

Blood (2014) 124 (21): 3676.

https://doi.org/10.1182/blood.V124.21.3676.3676

Published: 2014

Journal Articles

A Phase I/II Study Of Fludarabine, Cyclophosphamide, Rituximab and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy In Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Leukemia (SLL)

Raya Mawad, MD, Ajay K. Gopal, MD, Oliver W. Press, MD, PhD, David G. Maloney, MD, PhD, Stephen H. Petersdorf, MD, Troy Wadsworth, MD, Trevor W. Dennie, MD, Yoshio Inoue, MD, Karl J. Schultheiss, MD, Kiarash Kojouri, MD, MPH, Kelly M. Smith, MD, Britt Kammerer, John M. Pagel, MD, PhD

Blood (2013) 122 (21): 4191.

https://doi.org/10.1182/blood.V122.21.4191.4191

Published: 2013

Journal Articles

Specific Features Identify Patients with Relapsed/Refractory Mantle Cell Lymphoma Benefitting From Autologous Hematopoietic Cell Transplantation.

Ryan D. Cassaday, MD, Katherine A. Guthrie, PhD, Lihua E. Budde, MD, PhD, Leslie Thompson, Brian G. Till, MD, Oliver W. Press, MD, PhD, Thomas Chauncey, MD, PhD, John M. Pagel, MD, PhD, Stephen H. Petersdorf, MD, William I. Bensinger, MD, Leona Holmberg, MD, PhD, Andrei R. Shustov, MD, Damian J. Green, MD, Edward N. Libby, III, MD, David G. Maloney, MD, PhD, Ajay K. Gopal, MD

Blood (2012) 120 (21): 3082.

https://doi.org/10.1182/blood.V120.21.3082.3082

Published: 2012

Journal Articles

KIT Mutations Are Rare Among Elderly AML Patients: A SWOG Report

Fabiana Ostronoff, MD, Megan Othus, PhD, Phoenix A. Ho, MD, Stephen H. Petersdorf, MD, Jeanne E. Anderson, MD, John E. Godwin, MD, MS, Cheryl L Willman, MD, Jerald P. Radich, MD, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD, Soheil Meshinchi, MD, PhD

Blood (2011) 118 (21): 2510.

https://doi.org/10.1182/blood.V118.21.2510.2510

Published: 2011

Journal Articles

The Pre-Transplant Mantle Cell Lymphoma International Prognostic Index Predicts Overall and Progression-Free Survival Following High-Dose Therapy and Autologus Stem Cell Transplant for Mantle Cell Lymphoma

Leslie A Thompson, Katherine A Guthrie, Lihua Elizabeth Budde, MD, PhD, Brian G. Till, MD, Oliver W. Press, MD, PhD, Thomas Chauncey, MD, PhD, John M. Pagel, MD, PhD, Stephen H. Petersdorf, MD, William I Bensinger, MD, Leona Holmberg, MD., PhD, Andrei R. Shustov, MD, Damian J. Green, MD, David G. Maloney, MD, PhD, Ajay K. Gopal, MD

Blood (2011) 118 (21): 2026.

https://doi.org/10.1182/blood.V118.21.2026.2026

Published: 2011

Journal Articles

Prevalence and Clinical Implications of IDH2 R140 and R172 Mutations in Older Adults with AML: A Report From SWOG,

Phoenix A. Ho, MD, Megan Othus, PhD, Fabiana Ostronoff, MD, Stephen H. Petersdorf, MD, Jeanne E. Anderson, MD, John E. Godwin, MD, MS, Cheryl L Willman, MD, Jerald P. Radich, MD, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD, Soheil Meshinchi, MD, PhD

Blood (2011) 118 (21): 3516.

https://doi.org/10.1182/blood.V118.21.3516.3516

Published: 2011

Journal Articles

DNMT3A Mutations Independently Predict Poor Outcome in Older AML Patients: A SWOG Report,

Blood (2011) 118 (21): 3519.

https://doi.org/10.1182/blood.V118.21.3519.3519

Published: 2011

Journal Articles

Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm,

Pamela S Becker, MD, PhD, Bruno C. Medeiros, MD, Frederick R. Appelbaum, MD, Bart Lee Scott, MD, Paul C. Hendrie, MD, PhD, Barry Storer, PhD, Sherry Pierce, RN, BS, Stephen H. Petersdorf, MD, Elihu H. Estey, MD

Blood (2011) 118 (21): 3617.

https://doi.org/10.1182/blood.V118.21.3617.3617

Published: 2011

Journal Articles

Survival After Failure of Initial Therapy for Newly-Diagnosed or Relapsed/Refractory AML At An Academic Center: Subsequent Clinical Trial Vs. Not

Ravinder K Sandhu, Jack M. Lionberger, MD, PhD, Megan Othus, PhD, John M. Pagel, MD, PhD, Kathleen ShannonDorcy, RN, PhD, Paul C. Hendrie, MD, PhD, Stephen H. Petersdorf, MD, Pamela S Becker, MD, PhD, Frederick R. Appelbaum, M.D., Elihu H Estey, MD

Blood (2011) 118 (21): 1497.

https://doi.org/10.1182/blood.V118.21.1497.1497

Published: 2011

Journal Articles

Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Speed of Neutrophil and Platelet Recovery

Laura F Newell, MD, Ravinder K Sandhu, Pamela S Becker, MD, PhD, John M. Pagel, MD, PhD, Paul C. Hendrie, MD, PhD, Roland B. Walter, MD, PhD, Stephen H. Petersdorf, MD, Kathleen Shannon Dorcy, RN, MN, Ph.C, Janis L. Abkowitz, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2011) 118 (21): 1498.

https://doi.org/10.1182/blood.V118.21.1498.1498

Published: 2011

Journal Articles

Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data

Laura F Newell, MD, Megan Othus, PhD, Roland B. Walter, MD, PhD, Stephen H. Petersdorf, MD, Thomas Chauncey, MD, PhD, Jeanne E. Anderson, MD, John E. Godwin, MD, MS, Kenneth J. Kopecky, PhD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2011) 118 (21): 1446.

https://doi.org/10.1182/blood.V118.21.1446.1446

Published: 2011

Journal Articles

Prognostic Implications of the IDH1 synonymous SNP rs11554137 In Pediatric and Adult AML: a Children's Oncology Group and Southwest Oncology Group Study

Blood (2010) 116 (21): 2737.

https://doi.org/10.1182/blood.V116.21.2737.2737

Published: 2010

Journal Articles

Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens.

Pamela S. Becker, MD, PhD, Hagop Kantarjian, MD, Frederick R. Appelbaum, MD, Stephen H. Petersdorf, MD, Barry Storer, PhD, Sherry A. Pierce, RN, BS, Jianqin Shan, PhD, Paul C. Hendrie, MD, PhD, John M. Pagel, MD, PhD, Andrei Shustov, MD, Derek L. Stirewalt, MD, Stefan Faderl, MD, Elizabeth Harrington, RN, Elihu H. Estey, MD

Blood (2010) 116 (21): 1065.

https://doi.org/10.1182/blood.V116.21.1065.1065

Published: 2010

Journal Articles

Evaluation of Early Discharge After Hospital Treatment of Neutropenic Fever In Acute Myelogenous Leukemia (AML).

Victor A. Chow, Kathleen Shannon Dorcy, RN, MN, Ph.C, Stephen H. Petersdorf, MD, Kelda M. Gardner, PA-C, Pamela S. Becker, MD, PhD, Roland B. Walter, MD, PhD, John M. Pagel, MD, PhD, Paul C. Hendrie, MD, PhD, Andrei R. Shustov, MD, Janis L. Abkowitz, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2010) 116 (21): 3806.

https://doi.org/10.1182/blood.V116.21.3806.3806

Published: 2010

Journal Articles

Over-Expression of Novel IRF8 Splice Variants Is Associated with a Significant Decrease In Relapse-Free Survival In Adult AML Patients.

Era L. Pogosova-Agadjanyan, Kenneth J. Kopecky, PhD, Hana Lee, Jeanne E. Anderson, MD, John E. Godwin, MD, MS, Alan F. List, Soheil Meshinchi, MD, PhD, Vivian Oehler, MD, Stephen H. Petersdorf, MD, Cheryl L. Willman, MD, Frederick R. Appelbaum, MD, Jerald P. Radich, MD, Derek L. Stirewalt, MD

Blood (2010) 116 (21): 1679.

https://doi.org/10.1182/blood.V116.21.1679.1679

Published: 2010

Journal Articles

Outcomes of Early Relapse Following Non-Myeloablative Allogeneic Transplant for Lymphoma.

Ron Ram, MD, Ted Gooley, David G. Maloney, MD, PhD, Oliver W. Press, MD, John M. Pagel, MD, PhD, Stephen H. Petersdorf, MD, Andrei R. Shustov, MD, Mary E.D. Flowers, MD, Brenda M. Sandmaier, MD, Rainer F. Storb, MD, Ajay K. Gopal, MD

Blood (2009) 114 (22): 1204.

https://doi.org/10.1182/blood.V114.22.1204.1204

Published: 2009

Journal Articles

Outcomes after Autologous Stem Cell Transplantation for Mantle Cell Lymphoma Based on Remission Status and Induction Chemotherapy Regimen.

Brian G. Till, MD, Theodore A. Gooley, PhD, Nathan Crawford, Ajay K. Gopal, MD, David G. Maloney, MD, PhD, Stephen H. Petersdorf, MD, John M. Pagel, MD, PhD, Leona Holmberg, MD, William Bensinger, MD, Oliver W. Press, MD, PhD

Blood (2007) 110 (11): 1905.

https://doi.org/10.1182/blood.V110.11.1905.1905

Published: 2007

Journal Articles

High-Dose Therapy and Autologous Stem Cell Transplantation for Chemoresistant Diffuse Large B Cell Lymphoma: The Seattle Experience.

Jonathan A. Gutman, MD, Ted A. Gooley, PhD, Jacob Nourigat, John M. Pagel, MD, PhD, Oliver W. Press, MD, PhD, Leona A. Holmberg, MD, PhD, William I. Bensinger, MD, Stephen H. Petersdorf, MD, Ajay K. Gopal, MD

Blood (2007) 110 (11): 5097.

https://doi.org/10.1182/blood.V110.11.5097.5097

Published: 2007

Journal Articles

Efficacy of High-Dose Therapy and Autologous Stem Cell Transplantation for Chemoresistant Hodgkin’s Lymphoma.

Tracee L. Metcalfe, MD, Ted A. Gooley, PhD, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD, Stephen H. Petersdorf, MD, William Bensinger, MD, Leona Holmberg, MD, PhD, David G. Maloney, MD, PhD, Ajay K. Gopal, MD

Blood (2005) 106 (11): 2081.

https://doi.org/10.1182/blood.V106.11.2081.2081

Published: 2005

Journal Articles

The Impact of Histologic Grade on the Outcome of High-Dose Therapy and Autologous Stem Cell Transplantation for Follicular Lymphoma.

Rosalyn N. Pham, BS, Ted A. Gooley, Ph.D, Grant E. Keeney, BA, Oliver W. Press, MD, Ph.D, John M. Pagel, MD, Ph.D, Stephen H. Petersdorf, MD, David G. Maloney, MD, Ph.D, Ajay K. Gopal, MD

Blood (2005) 106 (11): 679.

https://doi.org/10.1182/blood.V106.11.679.679

Published: 2005

NARROW

Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG

A Phase I/II Study Of Fludarabine, Cyclophosphamide, Rituximab and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy In Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Leukemia (SLL)

Specific Features Identify Patients with Relapsed/Refractory Mantle Cell Lymphoma Benefitting From Autologous Hematopoietic Cell Transplantation.

KIT Mutations Are Rare Among Elderly AML Patients: A SWOG Report

The Pre-Transplant Mantle Cell Lymphoma International Prognostic Index Predicts Overall and Progression-Free Survival Following High-Dose Therapy and Autologus Stem Cell Transplant for Mantle Cell Lymphoma

Prevalence and Clinical Implications of IDH2 R140 and R172 Mutations in Older Adults with AML: A Report From SWOG,

DNMT3A Mutations Independently Predict Poor Outcome in Older AML Patients: A SWOG Report,

Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm,

Survival After Failure of Initial Therapy for Newly-Diagnosed or Relapsed/Refractory AML At An Academic Center: Subsequent Clinical Trial Vs. Not

Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Speed of Neutrophil and Platelet Recovery

Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data

Prognostic Implications of the IDH1 synonymous SNP rs11554137 In Pediatric and Adult AML: a Children's Oncology Group and Southwest Oncology Group Study

Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens.

Evaluation of Early Discharge After Hospital Treatment of Neutropenic Fever In Acute Myelogenous Leukemia (AML).

Over-Expression of Novel IRF8 Splice Variants Is Associated with a Significant Decrease In Relapse-Free Survival In Adult AML Patients.

Outcomes of Early Relapse Following Non-Myeloablative Allogeneic Transplant for Lymphoma.

Outcomes after Autologous Stem Cell Transplantation for Mantle Cell Lymphoma Based on Remission Status and Induction Chemotherapy Regimen.

High-Dose Therapy and Autologous Stem Cell Transplantation for Chemoresistant Diffuse Large B Cell Lymphoma: The Seattle Experience.

Efficacy of High-Dose Therapy and Autologous Stem Cell Transplantation for Chemoresistant Hodgkin’s Lymphoma.

The Impact of Histologic Grade on the Outcome of High-Dose Therapy and Autologous Stem Cell Transplantation for Follicular Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only